紅日藥業(300026.SZ):控股股東累計增持5.04% 持股升至21.26%表決權升至27.27%
格隆匯11月19日丨紅日藥業(300026.SZ)公佈,為進一步鞏固興城集團的控股地位,2019年5月6日至2019年11月14日,興城集團通過深交所交易系統以集中競價交易方式增持公司1.5150億股股份,佔公司總股本的5.04%。
此次權益變動完成後,興城集團直接持有公司6.3914億股股份,佔公司總股本的21.26%;興城集團在公司中擁有表決權的股份數量合計為8.1980億股,佔公司總股本的27.27%。興城集團所持有公司股份累計被質押2.4382億股,佔其所持股份的38.15%,佔公司總股本的8.11%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.